文献速递胃肠外科肝胆胰外科围术期管理与 ERAS

袖状胃切除与Roux-en-Y胃旁路术对活检证实非酒精性脂肪性肝病的影响

Impact of sleeve gastrectomy and Roux-en-Y gastric bypass on biopsy-proven non-alcoholic fatty liver disease.
PubMed 文献 · Surg Endosc · 2019-07-29

本研究在单中心2008至2015年间对3813例初次行RYGB或SG的患者行术中肝活检,筛选出487例活检证实NAFLD且基线ALT或AST≥40 IU/L者,按1:4倾向评分匹配SG与RYGB,比较至少术后1年肝功能变化。中位随访4年,84%患者肝功能恢复正常,SG与RYGB组正常化比例无显著差异(82% vs. 84%,p=0.66),两术式均显著降低AST和ALT且组间无差异。

要点

  • 减重术后多数活检证实NAFLD患者肝功能在术后1年内恢复正常并维持。
  • SG与RYGB在改善肝功能方面效果相似,正常化比例无显著差异。
  • 两术式均显著降低AST和ALT,组间比较无统计学差异。

核心结论

  • 在活检证实NAFLD/NASH且基线转氨酶异常的患者中,SG和RYGB术后多数患者肝功能恢复正常并维持至末次随访。
  • 两种减重术式在改善肝功能方面效果相似。

研究设计与样本

  • 单中心回顾性研究,2008至2015年3813例初次RYGB或SG术中行肝活检。
  • 筛选487例活检证实NAFLD且基线ALT或AST≥40 IU/L者,按1:4倾向评分匹配SG与RYGB。
  • 最终分析310例(加权),SG 62例、RYGB 248例,中位随访4年(范围1-10年)。

主要发现

  • 84%患者末次随访时肝功能恢复正常。
  • SG与RYGB组肝功能正常化比例无显著差异(82% vs. 84%,p=0.66)。
  • AST从基线(SG 49.1±21.5 vs. RYGB 49.3±22.0,p=0.93)降至末次随访(SG 28.0±16.5 vs. RYGB 26.5±15.5,p=0.33)。
  • ALT从基线(SG 61.7±30.0 vs. RYGB 59.4±24.9,p=0.75)降至末次随访(SG 27.2±21.5 vs. RYGB 26.1±19.2,p=0.52)。

临床怎么用

  • 对于活检证实NAFLD/NASH且转氨酶异常的减重手术患者,SG与RYGB均可作为改善肝功能的术式选择。
  • 术后应随访肝功能,多数患者在术后1年内恢复正常。

局限性

  • 单中心回顾性研究,样本经严格筛选和倾向评分匹配后分析310例(加权)。
  • 随访时间中位4年,范围1-10年,存在异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD)/steatohepatitis (NASH) is the hepatic manifestation of metabolic syndrome. Our aim was to study the long-term effects of sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB) on NAFLD/NASH. METHODS: Between 2008 and 2015, 3813 patients had an intraoperative liver biopsy performed at the time of primary RYGB and SG at a single academic center. Utilizing strict inclusion criteria, 487 patients with biopsy-proven NAFLD who had abnormal alanine aminotransferase (ALT) or aspartate aminotransferase (AST) values (≥ 40 IU/L) at baseline were identified. Matching of SG to RYGB patients (1:4) was performed via logistic regression and propensity scores adjusting for clinical and liver histological characteristics. Changes in liver function tests (LFTs) at least 1 year after surgery were compared to baseline values and between the surgical groups. RESULTS: A total of 310 (weighted) patients (SG n = 62, and RYGB n = 248) with a median follow-up time of 4 years (range, 1-10) were included in the analysis. The distribution of covariates was well-balanced after propensity matching. In 84% of patients, LFT values normalized after bariatric surgery at the last follow-up time. The proportions of patients having normalized LFT values did not differ significantly between the SG and RYGB groups (82% vs. 84%, p = 0.66). The AST decreased from (SG: 49.1 ± 21.5 vs. RYGB: 49.3 ± 22.0, p = 0.93) at baseline to (SG: 28.0 ± 16.5 vs. RYGB: 26.5 ± 15.5, p = 0.33) at the last follow-up. Similarly, a significant reduction in ALT values from (SG: 61.7 ± 30.0 vs. RYGB 59.4 ± 24.9, p = 0.75) at baseline to (SG: 27.2 ± 21.5 vs. RYGB: 26.1 ± 19.2, p = 0.52) at the last follow-up was observed. CONCLUSIONS: In patients with biopsy-proven NAFLD/NASH, abnormal LFTs are normalized in most SG and RYGB patients by the end of the first postoperative year and remain normal until the last follow-up. This study also suggests that both bariatric procedures are similarly effective in improving liver function.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Cherla DV, Rodriguez NA, Vangoitsenhoven R, et al. Impact of sleeve gastrectomy and Roux-en-Y gastric bypass on biopsy-proven non-alcoholic fatty liver disease. Surg Endosc. 2019. PMID: 31359195. doi:10.1007/s00464-019-07017-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。